Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
View / Open Files
Authors
Nguyen, Vinh
Dubreuil, Maureen
Strymish, Judith
Brophy, Mary
Publication Date
2021Journal Title
PLoS One
ISSN
1932-6203
Publisher
Public Library of Science (PLoS)
Volume
16
Issue
10
Pages
e0259061
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Fillmore, N., Bell, S., Shen, C., Nguyen, V., La, J., Dubreuil, M., Strymish, J., et al. (2021). Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.. PLoS One, 16 (10), e0259061. https://doi.org/10.1371/journal.pone.0259061
Abstract
Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.
Identifiers
External DOI: https://doi.org/10.1371/journal.pone.0259061
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330303
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.